<DOC>
	<DOCNO>NCT02392611</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) GS-5829 adult advance solid tumor lymphomas combination exemestane fulvestrant adult estrogen receptor positive breast cancer .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics , Pharmacodynamics GS-5829 Adults With Advanced Solid Tumors Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Key Group 1 : Histologically cytologically confirm advanced malignant solid tumor lymphoma ( subtype ) refractory intolerant standard therapy standard therapy available Group 2 : Postmenopausal woman advance stage estrogen receptor positive breast cancer candidate exemestane fulvestrant Group 3 : Individuals lymphoma limit diffuse large Bcell lymphoma peripheral Tcell lymphoma refractory intolerant standard therapy standard therapy available Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤ 1 Adequate organ function define follow : Hematologic : Platelets ≥ 100 x 10^9/L ; Hemoglobin ≥ 9.0 g/ dL ; Absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9/L ( without platelet transfusion growth factor within previous 7 day hematologic laboratory value obtain screen visit ) . Patients Group 3 lymphoma expansion may enrol ANC ≥ 1.0 x 10^9 /L ; Platelets ≥ 75 x 10^9 /L . Hepatic : Aspartate transaminase ( AST ) / Alanine transaminase ( ALT ) ≤ 2.5 x upper limit normal ( ULN ) ( liver metastasis present , ≤ 5 x ULN ) ; Total conjugate bilirubin ≤ 1.5 x ULN Renal : Serum creatinine ≤ 1.5 x ULN creatinine clearance ( CrCl ) ≥ 60 ml/min calculate cockcroftgault method Coagulation : International Normalized Ratio ( INR ) ≤ 1.2 Key Known brain metastasis leptomeningeal disease Myocardial infarction , symptomatic congestive heart failure ( New York Heart Association Classification &gt; Class II ) , unstable angina , serious uncontrolled cardiac arrhythmia within last 6 month study Day 1 Major surgery , define surgical procedure involve general anesthesia significant incision ( ie , large require placement central venous access , percutaneous feed tube , biopsy ) within 28 day first dose study drug History long QT syndrome whose corrected QT interval ( QTc ) measure ( Fridericia method ) screen prolong ( &gt; 450 m male &gt; 470 ms female ) . Individuals screenfail due criterion eligible rescreened Clinically significant bleeding within 28 day study Day 1 Known human immunodeficiency virus ( HIV ) infection HBsAG positive Hepatitis C virus ( HCV ) antibody positive No active anticoagulation within 7 day study Day 1 ; include acetylsalicylic acid , low molecular weight heparin , warfarin . Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Estrogen Receptor Positive Breast Cancer</keyword>
</DOC>